NCT07495215 — Yinghua Xu neoantigen vaccine trial
A Clinical Study on the Safety, Tolerability and Efficacy of Neoantigen-based Personalized mRNA Therapy iNeo-Vac-R01 Plus PD-1 Inhibitor in Adjuvant Treatment of Liver Cancer Post Radical Resection
Registry record
| Registry ID | NCT07495215 ↗ |
|---|---|
| Lead sponsor | Yinghua Xu |
| Collaborators | — |
| Phase | Phase 1/2 |
| Status | Recruiting |
| Indication | Hepatocellular Carcinoma (HCC) |
| Enrollment | 20 participants (target) |
| Start date | 2025-09-11 |
| Primary completion | 2028-12-31 (est.) |
| Last registry update | 27 Mar 2026 |
Every field above is mirrored from the study record on ClinicalTrials.gov (NCT07495215), which the sponsor maintains and which carries the full protocol summary, eligibility criteria, sites and contacts. No neoantigen vaccine is approved anywhere yet — every program here is investigational, and inclusion is not an endorsement. See the methodology for how the tracker is built.
Where this fits
Daily coverage of the modality, tumor type and players this study touches:
Related trials
FAQ
What phase is NCT07495215?
NCT07495215 (A Clinical Study on the Safety, Tolerability and Efficacy of Neoantigen-based Personalized mRNA Therapy iNeo-Vac-R01 Plus PD-1 Inhibitor in Adjuvant Treatment of Liver Cancer Post Radical Resection) is registered on ClinicalTrials.gov as Phase 1/2, sponsored by Yinghua Xu.
Is NCT07495215 recruiting?
As of the 2026-03-27 registry update, NCT07495215 is listed as "Recruiting". Eligibility criteria, study sites and contacts are maintained by the sponsor on the ClinicalTrials.gov record.
Who is running NCT07495215?
The lead sponsor is Yinghua Xu.
What condition does NCT07495215 study?
The registered condition is Hepatocellular Carcinoma (HCC). Primary completion is listed as 2028-12-31 (estimated).
Are results available for NCT07495215?
neoag.ai mirrors the registry's factual fields — sponsor, phase, status and dates — and does not publish trial results. Any posted results, publications, or outcome measures appear on the ClinicalTrials.gov record for NCT07495215.
Back to the full neoantigen vaccine trial tracker — 107 studies, refreshed daily from ClinicalTrials.gov. Background: primer, glossary, and the companies landscape.